Regeneron and Sanofi's Dupixent Secures FDA Approval for COPD Treatment
Regeneron Pharmaceuticals and Sanofi saw their shares rise on Friday following the FDA’s approval of their drug Dupixent for chronic obstructive pulmonary disease (COPD). This marks Dupixent as the first biologic medicine approved in the U.S. specifically for COPD, a condition that impairs airflow and harms lung function.